GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Gross Margin %

Clearmind Medicine (Clearmind Medicine) Gross Margin % : 0.00% (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Clearmind Medicine's Gross Profit for the three months ended in Jan. 2024 was $0.00 Mil. Clearmind Medicine's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. Therefore, Clearmind Medicine's Gross Margin % for the quarter that ended in Jan. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Clearmind Medicine's Gross Margin % or its related term are showing as below:


CMND's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9
* Ranked among companies with meaningful Gross Margin % only.

Clearmind Medicine had a gross margin of N/A% for the quarter that ended in Jan. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Clearmind Medicine was 0.00% per year.


Clearmind Medicine Gross Margin % Historical Data

The historical data trend for Clearmind Medicine's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Gross Margin % Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Gross Margin %
Get a 7-Day Free Trial - - - - -

Clearmind Medicine Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clearmind Medicine's Gross Margin %

For the Biotechnology subindustry, Clearmind Medicine's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Gross Margin % falls into.



Clearmind Medicine Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Clearmind Medicine's Gross Margin for the fiscal year that ended in Oct. 2023 is calculated as

Gross Margin % (A: Oct. 2023 )=Gross Profit (A: Oct. 2023 ) / Revenue (A: Oct. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Clearmind Medicine's Gross Margin for the quarter that ended in Jan. 2024 is calculated as


Gross Margin % (Q: Jan. 2024 )=Gross Profit (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Clearmind Medicine  (NAS:CMND) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Clearmind Medicine had a gross margin of N/A% for the quarter that ended in Jan. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Clearmind Medicine Gross Margin % Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine (Clearmind Medicine) Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.